Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXGD +5.08%41 5-Year Share Buyback Ratio is -1.70 as of Jun. 2026. GuruFocus rates IDXGD with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 176 Medical Diagnostics & Research companies, Interpace Biosciences ranks better than 59.09% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Interpace Biosciences's current 5-Year Share Buyback Ratio was -1.70%.
IDXGD's 5-Year Share Buyback Ratio is ranked better than 59.09% of 176
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.65
vs IDXGD: -1.70
Interpace Biosciences (OTCPK:IDXGD) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Interpace Biosciences 5-Year Share Buyback Ratio Related Terms
IDXGD vs PRPO, ADVB, BIOQ: 5-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences 5-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's 5-Year Share Buyback Ratio falls into.
Interpace Biosciences 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of -1.70 mean?
Interpace Biosciences (IDXGD) has a 5-Year Share Buyback Ratio of -1.70 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Interpace Biosciences and its competitors. According to the industry distribution chart, Interpace Biosciences ranks #72 out of 176 companies in the Medical Diagnostics & Research industry, placing it in the top 40.9%.
Is Interpace Biosciences' 5-Year Share Buyback Ratio too high?
Interpace Biosciences' current 5-Year Share Buyback Ratio is -1.70. Based on the distribution chart, Interpace Biosciences ranks #72 out of 176 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' 5-Year Share Buyback Ratio compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #72 out of 176 companies for 5-Year Share Buyback Ratio. This puts Interpace Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 5-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Interpace Biosciences and its competitors. Interpace Biosciences's current 5-Year Share Buyback Ratio is -1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXGD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $7.62 — trading 3709% above its estimated fair value. The current 5-Year Share Buyback Ratio is -1.70. Interpace Biosciences' overall GF Score™ is 41/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Interpace Biosciences (IDXGD), the current 5-Year Share Buyback Ratio is -1.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXGD) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $7.62 is trading 3709% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXGD:
5-Year Share Buyback Ratio: -1.70
GF Value™: $0.20 vs. price of $7.62 (3709% above fair value)
No single metric tells the full story. See the IDXGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXGD
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXGD has been successfully added to your 
